September 24, 2014
Brickell Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis and welcomes Charlie Stiefel and Bill Ju to Board of Directors.
June 30, 2014
Brickell announces licensing agreement for its novel retinoid therapy, BBI-3000, with Merz North America.
Focused on the development of novel therapies for the treatment of skin diseases.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.
Brickell Biotech, Inc. © 2014 All Rights Reserved.